High-level event on accelerating vaccines and therapeutic production for health security in Africa that comes from the mRNA Technology Transfer Programme followed by a cocktail reception at the French Mission

On the side-lines of the 77th World Health Assembly in Geneva, the Permanent Mission of France and the Medicines Patent Pool, in collaboration with the World Health Organization, hosted the parallel event Accelerating Vaccine and Therapeutic Production for Health Security in Africa.

In this session key elements were discussed regarding the sustainability of regional manufacturing capacity for therapeutics and vaccines in Africa including the example of WHO/MPP mRNA Technology Transfer Programme.

Opening message by WHO Director-General Dr Tedros

The mRNA Technology Transfer Programme and its 15 biomanufacturing partners



Watch the recording of the presentation and panel discussions:


View the recording




Agenda




Opening words from Hosts:


France’s Ambassador for Global Health: Anne-Claire Amprou


Minister of Health of Tunisia, Dr Ali Mrabet


Chair of MPP Board, Dr Marie-Paule Kieny




Presentation 1:


Platform for Harmonized African Health Products Manufacturing (PHAHM)


Dr Abebe, PAVM Coordinator


Presentation 2:


GAVI’s strategy for access and support to regional production in Africa


Dr Sania Nishtar, Executive Director GAVI




Panel discussion


Building a sustainable, realistic ecosystem


    

  • Policy Frameworks: Examination of necessary policy adaptations and regulatory harmonization to support local production.
    • 

  • Mitigating the vaccine manufacturing input material, supply chain challenges in Africa
    • 

  • Investment and Financing Models: Discuss innovative financing solutions and investment needed to scale up production capabilities
    • 

  • Education, Training, and Research: Focus on the importance of investing in education and training programs to build a skilled workforce, and the role of research institutions in supporting innovation.
    • 



Mar Martinez, European Commission


Michael Lusiola, CEO Biovax


Tenu Avafia, Deputy Executive Director, Unitaid


Frederik Kristensen, RVMC Managing Director (CEPI)


Amy Dietterich, Director of the Global Challenges Division at WIPO




Questions & Answers




Final remarks


Dr Jeremy Farrar, Chief Scientist, WHO